Literature DB >> 1867297

Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.

R B Nussenblatt1, A G Palestine, C C Chan, G Stevens, S D Mellow, S B Green.   

Abstract

Fifty-six patients with bilateral sight-threatening noninfectious intermediate or posterior uveitis participated in a randomized double-masked study of the use of cyclosporine vs prednisolone in their treatment. Applying the end-point definitions, visual acuity or vitreal haze improved in only 13 of 28 (46%) patients in each group. The macular edema resolved in seven of 15 patients of the cyclosporine-treated group, and in ten of 16 patients of the prednisolone-treated group (P = .376). Patients whose therapies failed both cyclosporine and prednisolone trials were treated with both drugs, which resulted in additional patient improvements. Secondary effects were observed in both therapeutic alternatives, the most notable being alterations in serum creatinine concentration and hypertension with the dosage of cyclosporine used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867297     DOI: 10.1016/s0002-9394(14)76692-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  38 in total

Review 1.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Standard and novel therapeutic approaches to Behçet's disease.

Authors:  Ahmet Gul
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 4.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

5.  Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy.

Authors:  F Boisgerault; I Khalil; V Tieng; F Connan; T Tabary; J H Cohen; J Choppin; D Charron; A Toubert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

6.  [Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists].

Authors:  F Mackensen; L Baydoun; J Garweg; A Heiligenhaus; T Hudde
Journal:  Ophthalmologe       Date:  2014-11       Impact factor: 1.059

Review 7.  Clinical trials in noninfectious uveitis.

Authors:  Jane S Kim; Jared E Knickelbein; Robert B Nussenblatt; H Nida Sen
Journal:  Int Ophthalmol Clin       Date:  2015

8.  Cyclosporin A in the ocular fluids of uveitis patients following long-term systemic administration.

Authors:  Paolo Mora; Uta Ceglarek; Francesca Manzotti; Laura Zavota; Arturo Carta; Raffaella Aldigeri; Jelka G Orsoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-06       Impact factor: 3.117

9.  High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen.

Authors:  Mohammad H Dastjerdi; Pedram Hamrah; Reza Dana
Journal:  Cornea       Date:  2009-12       Impact factor: 2.651

10.  Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study.

Authors:  Arnd Heiligenhaus; Beatrix Zurek-Imhoff; Martin Roesel; Maren Hennig; Daniela Rammrath; Carsten Heinz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.